Trial Profile
Real World Outcome of Different Administrations of Recombinant human endostatin Combined With Chemotherapy in Driver Gene Mutation Negative Advanced Non Small Cell Lung Cancer patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Endostatin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Oct 2018 New trial record
- 26 Sep 2018 Primary endpoint has been met. (median overall survival) as per results presented at the 19th World Conference on Lung Cancer
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer